Solvemed Group
Todd Verdoorn has extensive experience in the field of biopharmaceuticals and neuroscience. Todd currently serves as the Chief Scientist at Intuitive Quantitation, LLC, a company that provides strategic and tactical leadership for the development of new treatments for major diseases. In this role, Verdoorn focuses on delivering high-quality data, novel analysis, and clear communication to support critical decisions and advance successful development programs.
Prior to their current position, Verdoorn worked as a Research and Development Specialist at NeuroTrauma Sciences, LLC starting in 2020. Todd previously served as the Chief Scientific Officer at DiaMedica Inc. from 2016 to 2019, where they played a key role in the company's scientific operations.
Verdoorn's career also includes roles such as Vice President Neurobiology at NeuroTherapeutics Pharma, Inc., Chief Scientific Officer at Orasi Medical, Inc., and Chief Scientific Officer at SMART Bioscience. In these positions, they contributed significantly to the development of innovative technologies and treatments for diseases related to the central nervous system.
Earlier in their career, Verdoorn worked at Algos Preclinical Services, Inc., a biopharmaceutical start-up focused on chronic pain treatment strategies. Todd was a founding partner and served as the Chief Scientific Officer, raising initial venture funding and leading the scientific staff in drug discovery programs and contract research business development.
Before joining the private sector, Verdoorn worked as the Director of Neurology Drug Discovery at Bristol-Myers Squibb PRI. Todd provided strategic leadership and managed teams involved in neurology-focused drug discovery and development efforts, particularly in the areas of stroke and Alzheimer's disease.
Verdoorn began their career as a Postdoctoral Fellow at the Max Planck Institute for Medical Research and later became an Associate Professor at Vanderbilt University Medical Center. During this time, they established a well-funded laboratory, trained students and fellows, and published extensively in peer-reviewed journals.
Overall, Todd Verdoorn's work experience demonstrates their significant contributions to the field of biopharmaceuticals and neuroscience, particularly in the areas of drug discovery, scientific leadership, and strategic development.
Todd Verdoorn has a Ph.D. in Neurobiology from the University of North Carolina at Chapel Hill. Prior to that, they obtained a Bachelor of Arts degree in Chemistry from Central College. The specific start and end years for these educational experiences are not provided.
This person is not in any offices
Solvemed Group
At Solvemed Group, we believe in challenging the status quo of neurological care. Our founders experienced first-hand the grave consequences of poor diagnostic standards in neurodegenerative diseases. With the primary focus in Parkinson’s disease, we leverage our proprietary machine learning technology to develop novel diagnostic-predictive digitalbiomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools. In everything we do, we put the needs of patients and healthcare professionals first. We also happen to revolutionise drug discovery as our biomarkers enable disease-modifying drugs.We respond to the unmet needs of neurological patients by providing reliable, accurate, early diagnostics and monitoring tools for better quality care and treatment outcomes. Our work has the potential to improve healthcare systems by optimising relevant care pathways and reducing the financial burden imposed by inadequate diagnostics. Through our proprietary medical data repositories, we work with our biopharmaceutical industry partners driving clinical trial efficiency and making first-in-class disease-modifying drugs possible.Everything we do is strongly embedded in world-class science. Our global team of renowned scientists and technology experts works closely with clinical researchers from top research institutions, such as Oxford University, University College London, Harvard Medical School and Duke University, among other.